Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Investments (2017 - 2025)

Aclaris Therapeutics has reported Long-Term Investments over the past 6 years, most recently at $60.6 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $60.6 million for Q4 2025, down 32.88% from a year ago — trailing twelve months through Dec 2025 was $60.6 million (down 32.88% YoY), and the annual figure for FY2025 was $60.6 million, down 32.88%.
  • Long-Term Investments for Q4 2025 was $60.6 million at Aclaris Therapeutics, down from $71.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for ACRS hit a ceiling of $91.0 million in Q2 2023 and a floor of $7.2 million in Q2 2022.
  • Median Long-Term Investments over the past 5 years was $45.7 million (2024), compared with a mean of $50.0 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 79.07% in 2022 and later soared 1160.1% in 2023.
  • Aclaris Therapeutics' Long-Term Investments stood at $34.2 million in 2021, then plummeted by 64.25% to $12.2 million in 2022, then skyrocketed by 412.75% to $62.8 million in 2023, then skyrocketed by 43.86% to $90.3 million in 2024, then crashed by 32.88% to $60.6 million in 2025.
  • The last three reported values for Long-Term Investments were $60.6 million (Q4 2025), $71.3 million (Q3 2025), and $81.1 million (Q2 2025) per Business Quant data.